检测p16自身抗体作为宫颈癌患者潜在的早期诊断血清生物标志物
Detecting of p16 Autoantibody as a Potential Early Diagnostic Serum Biomarker in Patients with Cervical Cancer.
作者信息
Huangfu Mingmei, Liu Linlin, Xu Shuang, Li Siyao, Jiang Kuo, Sun Baosheng, Lee Kuang-Hui, Sun Shilong
出版信息
Clin Lab. 2016;62(6):1117-20. doi: 10.7754/clin.lab.2015.151024.
BACKGROUND
Over-expression of tumor-associated antigens (TAAs) may trigger secretion of their auto-antibodies. The present work was designed to test whether circulating antibody to P16 protein-derived antigens was altered in cervical cancer.
METHODS
141 cases of cervical cancer patients, 133 cases of cervical benign tumor patients, and 153 healthy volunteers matched in age were recruited. The level of circulating P16 auto-antibody was tested using an ELISA developed in-house with linear peptide antigens derived from the P16 protein.
RESULTS
The P16 auto-antibody in the malignant tumor group had a significantly higher level than the healthy control group and the benign tumor group (t = 4.016, p < 0.001; t = 3.879, p < 0.001). Patients with stage I cervical cancer have the highest level of P16 autoantibody and the sensitivity against > 90% specificity was 20.3%.
CONCLUSIONS
The circulating auto-antibody to P16 may be one of a series of potential biomarkers with early prognostic values for cervical cancer.
背景
肿瘤相关抗原（TAAs）的过度表达可能会引发自身抗体的分泌。本研究旨在检测宫颈癌患者循环中针对P16蛋白衍生抗原的抗体是否发生改变。
方法
招募141例宫颈癌患者、133例宫颈良性肿瘤患者以及153例年龄匹配的健康志愿者。使用自行研发的酶联免疫吸附测定法（ELISA），采用源自P16蛋白的线性肽抗原检测循环中P16自身抗体的水平。
结果
恶性肿瘤组中P16自身抗体水平显著高于健康对照组和良性肿瘤组（t = 4.016，p < 0.001；t = 3.879，p < 0.001）。I期宫颈癌患者的P16自身抗体水平最高，在特异性> 90%时敏感性为20.3%。
结论
循环中针对P16的自身抗体可能是一系列对宫颈癌具有早期预后价值的潜在生物标志物之一。
Zotero 插件